®
PRESS COVERAGE
Dec 3, 2025
Renerva Inc. approved for first-in-human FDA clinical trials
More than two million people in the U.S. are amputees, and an estimated 500,000 new extremity amputations occur each year because of trauma, disease, or surgical complications. Offering new hope, however, a medical device startup from the University of Pittsburgh has just reached a major milestone to improve care for individuals living with extremity amputations and other conditions causing nerve injury.
PRESS COVERAGE
Dec 3, 2025
Renerva Receives FDA IDE Approval to Commence First-in-Human Study of its Renerva PNM-CAP™ Device for Neuroma Pain
Renerva, Inc., a medical device company developing solutions for peripheral nerve repair, today announced it has received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) to initiate a first-in-human (FIH) clinical study for its Renerva PNM-CAP™ device.
PRESS COVERAGE
Dec 3, 2025
Renerva Begins First-in-Human Study for Novel Device to Prevent Neuroma Pain
Renerva, Inc., a Center for Life Science Ventures client developing medical devices for peripheral nerve repair, has received approval from the U.S. Food and Drug Administration to launch a first-in-human clinical study of its Renerva PNM-CAP™ nerve-cap device.
PRESS COVERAGE
Jan 9, 2020
Nerve-healing startup Renerva joins McGovern incubator
Renerva, a medical startup that is developing an injectable gel to speed the healing of damaged nerves and creating an off-the-shelf nerve-graft product that may spare patients life-long disability, has joined Cornell’s McGovern Center life sciences business incubator.